A Study to Evaluate Erlotinib in Patients With Advanced or Metastatic Breast Cancer During or Following Chemotherapy
Status:
Completed
Trial end date:
2002-10-01
Target enrollment:
Participant gender:
Summary
This is a Phase II, multicenter trial of single-agent treatment with OSI 774 in patients with
histologically confirmed, incurable, locally advanced or metastatic breast cancer. Patients
must have measurable disease.